**Personalized Care and Tailored Treatment Plans for Gynecologic Cancers Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches**

**Activity Description**

The treatment landscape for gynecologic cancers—such as ovarian, endometrial, and cervical cancers—is advancing rapidly. Antibody drug conjugates (ADCs), immunotherapy, PARP inhibitors, combination approaches, and other innovative strategies have become integral parts of standard care, with ongoing research exploring numerous combination options. These innovations require precise molecular classification to help personalize treatment decisions. In light of these advancements, how can oncology nurses effectively translate the extensive clinical evidence for established and emerging therapies into practical, real-world care for patients with gynecologic cancers? This workshop will empower nurses with essential insights into modern therapeutic approaches for managing gynecologic cancers, including insight on the essentials of diagnostic testing and patient support throughout treatment, with a focus on managing adverse events. Case studies will provide actionable guidance on patient education and support.

**Educational Objectives**

Upon completion of this activity, participants should be better able to:

• Summarize the safety and efficacy data for the use of personalized approaches (eg, immunotherapy, ADCs, PARP inhibitors, other emerging options) for the treatment of gynecologic cancers

• Incorporate nurse-led approaches to integrate individualized management and education plans for patients with endometrial, cervical, and ovarian cancers, including diagnostic testing, safety considerations, and ongoing clinical trial opportunities

• Utilize efficient team-based safety techniques to promptly recognize, manage, and advise patients on a range of adverse events associated with therapies for endometrial, cervical, and ovarian cancers

**Accreditation, Support, and Credit**

 In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab. Nurses’ successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology